2026-05-05T14:30:25Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/136202025-03-10T14:27:49Zcom_20.500.12105_5571com_20.500.12105_2404com_20.500.12105_2403col_20.500.12105_5714

00925njm 22002777a 4500 dc Rodríguez-Pinilla, Elvira author Mejías-Pavón, C author Dequino, GV author Fernández-Martín, P author Martínez-Frías, María Luisa author 2002-10 Topical costicosteroids (TC) are relatively frequently used drugs, but little is known of the safety of their use during Pregnancy. Data from the Spanish Collaborative Study of Congenital Malformations (ECEMC), an ongoing hospital– Based case–control study and surveillance system, was analyzed. The use of TC during pregnancy in Spain has increased significantly during the period 1977–2001. At present, around 0,8% of the pregnant women received a treatment with TC during any moment of gestation. The overall OR for congenital defects after prenatal exposure to TC during the first trimester of pregnancy was 1.45 (CI:0.91–2.30; p=0.10). Thus, treatments with TC in pregnancy do not appear to noticeably increase the risk for congenital defects. Boletín del ECEMC: Rev Dismor Epidemiol 2002; V (nº 1): 49-54 0210–3893 Boletín del ECEMC: Revista de Dismorfología y Epidemiología http://hdl.handle.net/20.500.12105/13620 Dismorfología Anomalías congénitas Epidemiología Utilización de corticosteroides por vía tópica durante la gestación